Image may be NSFW.
Clik here to view.
Fresenius (ETR:FRE) filed counterclaims against generic drugmaker Akorn Inc. (NSDQ:AKRX) this week in Delaware Chancery Court, alleging that Akorn tried to defraud the FDA with falsified testing data.
Akorn filed suit against Fresenius one day after the company walked away from a $4.75 billion deal to acquire Akorn. Fresenius cited an investigation that found material breaches of FDA data integrity requirements relating to Akorn’s operations.
Get the full story at our sister site, Drug Delivery Business News.
The post Fresenius fires back at Akorn with counterclaims following failed merger appeared first on MassDevice.
